Generic Statins May Save Medicare $8.2 B

FEBRUARY 01, 2006

Increased use of generic cholesterol drugs by the nation's seniors could reduce total Medicare costs by $8.2 billion next year, officials at Consumers Union (CU) said. "Lower-cost cholesterol drugs are just as effective and safe, and the savings from switching to them could be dramatic,"CU said in its on-line "Best Buy Drugs"report.

Much of the savings envisioned by the consumer group would come from persuading patients to switch from Pfizer's Lipitor to the generic lovastatin, or to generic versions of Zocor (simvastatin), which are expected to reach the market later this year.

Statins such as Lipitor are expected to cost Medicare and its beneficiaries $14 billion next year alone, and the cost of these drugs could reach as much as $215 billion between now and 2015—about 11% of all spending under the new Medicare prescription drug benefit, CU said.

According to CU, Lipitor should remain the drug of choice for patients whose cholesterol is significantly elevated or who need a more potent statin because they are at higher risk of heart attack and stroke. Others who require only a modest reduction in cholesterol should be switched to generics, the organization said.


The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


Pharmacy Times Strategic Alliance

Conference Coverage
News from the year's biggest meetings

Pharmacist Education
Clinical features with downloadable PDFs


Personalize the information you receive by selecting targeted content and special offers.